Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On December 14, 2017, David Apelian, M.D., Ph.D. delivered his resignation as Executive Vice President, Chief Medical Officer of Achillion Pharmaceuticals, Inc. (the “Company”), effective December 28, 2017. Dr. Apelian is leaving the Company to pursue another professional opportunity. A retained search for a new Chief Medical Officer has been initiated with Russell Reynolds Associates.
On December 14, 2017, Avner Ingerman, M.D., Senior Vice President, assumed responsibility for development operations.
About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.
